Allstate Corp trimmed its holdings in Waters Corporation (NYSE:WAT - Free Report) by 19.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,331 shares of the medical instruments supplier's stock after selling 2,459 shares during the quarter. Allstate Corp's holdings in Waters were worth $3,875,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. bought a new position in shares of Waters during the 2nd quarter worth about $3,182,191,000. Janus Henderson Group PLC boosted its stake in Waters by 27.0% during the first quarter. Janus Henderson Group PLC now owns 1,638,772 shares of the medical instruments supplier's stock worth $488,028,000 after buying an additional 348,379 shares in the last quarter. Geode Capital Management LLC increased its holdings in Waters by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier's stock valued at $602,921,000 after buying an additional 8,590 shares during the period. Invesco Ltd. increased its stake in Waters by 32.3% in the third quarter. Invesco Ltd. now owns 1,472,419 shares of the medical instruments supplier's stock valued at $441,446,000 after acquiring an additional 359,596 shares during the period. Finally, Veritas Asset Management LLP boosted its holdings in Waters by 112.3% during the fourth quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier's stock valued at $471,447,000 after purchasing an additional 656,436 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently commented on WAT shares. The Goldman Sachs Group raised their target price on Waters from $380.00 to $425.00 and gave the stock a "buy" rating in a research report on Tuesday, July 14th. Wolfe Research assumed coverage on Waters in a research report on Tuesday, June 2nd. They issued an "outperform" rating and a $425.00 price target on the stock. HSBC increased their price objective on Waters from $415.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, June 3rd. Guggenheim reissued a "buy" rating and set a $440.00 price objective on shares of Waters in a report on Wednesday, July 8th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $400.00 target price on shares of Waters in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $420.35.
Read Our Latest Research Report on WAT
Insider Buying and Selling
In other Waters news, Director Christopher A. Kuebler sold 3,626 shares of the company's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the transaction, the director directly owned 17,808 shares in the company, valued at approximately $7,086,515.52. This represents a 16.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.31% of the stock is currently owned by insiders.
Waters Stock Performance
Shares of Waters stock opened at $412.37 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.86 and a quick ratio of 1.29. The firm has a 50 day simple moving average of $381.79 and a 200 day simple moving average of $347.02. Waters Corporation has a fifty-two week low of $282.77 and a fifty-two week high of $421.74. The firm has a market cap of $40.52 billion, a P/E ratio of 102.84, a P/E/G ratio of 2.39 and a beta of 1.19.
Waters (NYSE:WAT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.01 by $0.04. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.62 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%.The business's revenue for the quarter was up 113.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.95 EPS. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Sell-side analysts predict that Waters Corporation will post 14.57 earnings per share for the current fiscal year.
About Waters
(
Free Report)
Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.
Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.
See Also
Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
